Meta-analysis of Adverse Reactions of Zhengqingfengtongning Sustained Release Tablets

Abstract

Abstract: Objective To systematically review the characteristics of adverse reactions of Zhengqingfengtongning sustained release tablets, and to provide scientific evidence for related control and prevention work. Methods Databases such as CNKI, VIP, WanFang Data were searched for studies investigating the characteristics of adverse reactions of Zhengqingfengtongning sustained release tablets between 2000~2015. According to the inclusion and exclusion criteria, the data were extracted and the methodological quality of included studies was assessed. Then Meta-analysis was performed by using the RevMan 5.3 software. Results Forty-four studies involving 1 700 cases of treatment group and 1 688 cases of control group were included. The results of pooled analysis showed that the overall adverse reaction incidence of Zhengqingfengtongning was 14.2% and the risk was 0.83 times of the control group (RR: 0.83, 95% CI: 0.72~0.96). Sub-group analysis showed that the adverse reaction incidence of Zhengqinfengtongning alone group was 11.8%, 0.83 times of the risk for the control group (RR: 0.83, 95% CI: 0.62~1.10); the adverse reaction incidence of Zhengqinfengtongning combined use group(the control group treatments + Zhengqingfengtongning) was 14.8%, 0.91 times of the risk for the control group (RR: 0.91, 95% CI: 0.74~1.11); the types of adverse reactions mainly included rash reaction(8%), the risk was three times for the control group (RR: 3.00, 95% CI: 2.21~4.08); gastrointestinal reaction3.8% ,the risk was 0.58 times for the control group (RR: 0.58, 95% CI: 0.44~0.76); the other kind of adverse reactions 2.4%, the risk was 0.33 times for the control group (RR: 0.33, 95% CI: 0.24~0.44). Conclusion The treatment groups administrated Zhengqinfengtongning had a higher rash itchy reaction rate than the control groups, but the occurrence of gastrointestinal reaction and others were lower than the control groups. From the point of the overall adverse reactions, combined use of Zhengqinfengtongning had less adverse reaction incidences than the control group.

Key words: Zhengqingfengtongning sustained release tablet, adverse reaction, Meta-analysis

CLC Number:

R994.11

XIE Zhi-Xin, WANG Mian, LONG Li-Ping, QIU Ping, WEN Ying-Yi. Meta-analysis of Adverse Reactions of Zhengqingfengtongning Sustained Release Tablets[J]. Chinese Journal of Pharmacovigilance, 2016, 13(9): 547-556.

References

[1] Shaikh N, Morone N E, Bost J E, et al. Prevalence of urinary tract infection in childhood: a meta-analysis[J]. Pediatr Infect Dis J, 2008,27(4): 302-308.
[2] Loney P L, Chambers L W, Bennett K J, et al. Critical appraisal of the health research literature: prevalence or incidence of a health problem[J]. Chronic Dis Can, 1998, 19(4): 170-176.
[3] Juni P, Witschi A, Bloch R, et al. The hazards of scoring the quality of clinical trials for meta-analysis[J]. JAMA, 1999, 282(11): 1054-1060.
[4] 杨德才,郑新春. 正清风痛宁缓释片治疗类风湿关节炎疗效观察[J]. 药品评价, 2005, 2(2):152-153.
[5] 范颖方. 产后风湿饮治疗产后风湿症状的临床研究[D].山东中医药大学, 2005.
[6] 孙淑银,兰红梅. 正清风痛宁缓释片与甲氨喋呤联合治疗类风湿性关节炎62例小结[J]. 中医药导报, 2006, 12(1):40-41.
[7] 许超尘. 正清风痛宁缓释片治疗类风湿关节炎80例临床观察[J].中医药导报, 2006, 12(11):33-35.
[8] 黄传兵,陈晓雯,刘健,等. 正清风痛宁缓释片联合柳氮磺胺吡啶治疗强直性脊柱炎临床研究[J]. 中国中医药信息杂志,2007, 14(1):56-57.
[9] 林志翔,戴禄寿,郑良成,等. 正清风痛宁对类风湿性关节炎的治疗价值[J]. 临床军医杂志, 2007, 35(2):245-247.
[10] 夏海波,文锋,孙金龙. 正清风痛宁缓释片治疗幼年特发性关节炎的疗效观察[J]. 中国实用医药, 2007, 2(8):64.
[11] 林志翔,郑良成,戴益琛,等. 中西医联合治疗系统性红斑狼疮17例[J]. 实用医学杂志, 2007, 23(19):3103-3105.
[12] 王智华,刘健,郭雯,等. 健脾化湿通络法对类风湿关节炎患者生活质量的影响[J]. 中国临床保健杂志, 2007, 10(6):586-588.
[13] 刘维, 张磊, 刘晓亚. 正清风痛宁治疗强直性脊柱炎60例疗效观察[C]// 全国中西医结合强直性脊柱炎专题研讨会论文汇编.2007.
[14] 杨德才, 郑新春. 正清风痛宁缓释片治疗强直性脊柱炎疗效观察[C]// 全国中西医结合强直性脊柱炎专题研讨会. 2007.
[15] 李亚萍. 正清风痛宁缓释片治疗类风湿关节炎疗效观察[J]. 中医正骨, 2008, 2(4):50.
[16] 曾志成,彭清华. 正清风痛宁缓释片替代激素治疗前葡萄膜炎临床观察[J]. 中医药导报, 2008, 14(8):62-63.
[17] 李忆农,冯修高,张胜利,等. 正清风痛宁联合甲氨喋呤治疗类风湿关节炎[J]. 实用药物与临床, 2008, 11(5):285-287.
[18] 韩武臣,黄源. 正清风痛宁联合甲氨蝶呤对类风湿性关节炎的治疗价值[J]. 西部医学, 2009, 21(5):766-768.
[19] 罗来敏,胡翔,喻任国. 正清风痛宁治疗糖尿病肾病的疗效及对血浆内皮素水平的影响[J]. 江西医学院学报, 2009, 49(6):88-89.
[20] 夏棣其,杨峻厚. 正清风痛宁序贯治疗髋关节骨性关节炎35例[J].河南中医, 2009, 29(8):818-819.
[21] 杨春华. 甲氨蝶呤联合中药治疗类风湿性关节炎的疗效观察[J].中国初级卫生保健, 2009, 23(10):130-131.
[22] 许东云,许云香,邹雁宁. 寒湿方治疗类风湿性关节炎40例临床观察[J]. 云南中医中药杂志, 2009, 30(11):14-15.
[23] 彭江云,李兆福,刘维超,等. 蠲痹颗粒治疗类风湿关节炎40例临床疗效观察[J]. 云南中医中药杂志, 2009, 30(12):12-14.
[24] 黄智胜,王娜.正清风痛宁缓释片治疗类风湿关节炎的临床观察[J].河北医药, 2010, 32(1):59-60.
[25] 王文琴. 甲氨蝶呤联合正清风痛宁缓释片治疗类风湿关节炎120例[J]. 浙江实用医学, 2010, 15(4):280-281.
[26] 胡谦, 官晓红, 练颖,等. 来氟米特与甲氨喋呤联合正清风痛宁治疗类风湿性关节炎疗效观察[J]. 现代临床医学, 2010,36(5):338-340.
[27] 林昌松, 徐强, 陈纪藩,等. 二藤通痹合剂联合正清风痛宁缓释片治疗RA的随机对照研究[C]// 全国中西医结合风湿病学术会议. 2010.
[28] 林志翔, 戴禄寿, 戴益琛,等. 正清风痛宁治疗强直性脊柱炎的临床疗效观察[J]. 临床军医杂志, 2010, 38(5).
[29] 林志翔, 姜元芹, 戴益琛,等. 小剂量沙利度胺联合中药治疗白塞病的疗效[J]. 实用药物与临床, 2011, 14(1):75-77.
[30] 林昌松, 姬森国, 徐强,等. 二藤通痹合剂联合正清风痛宁缓释片治疗类风湿关节炎30例临床研究[J]. 中医杂志, 2011,52(15):1293-1296.
[31] 赵红英, 黄亚增, 张骏,等. 正清风痛宁联合塞来昔布治疗膝关节骨性关节炎40例[J]. 医药导报, 2011, 30(7):907-910.
[32] 柴廉明, 范伏元. 正清风痛宁治疗强直性脊柱炎活动期28例临床观察[J]. 中医药导报, 2011, 17(6):45-47.
[33] 张芳, 李晶晶. 正清风痛宁缓释片联合西药治疗活动性类风湿关节炎53例临床观察[J]. 中医药导报, 2011, 17(8):20-22.
[34] 李霞. 正清风痛宁缓释片治疗类风湿关节炎40例临床观察[J].中医药导报, 2012, 18(3):79-80.
[35] 邓校征. 正清风痛宁缓释片治疗腰椎骨关节炎的临床研究[D].湖南中医药大学, 2012.
[36] 吴水平. 正清风痛宁治疗类风湿性关节炎风湿热痹证的临床观察[D]. 湖南中医药大学, 2012.
[37] 严晶晶. 正清风痛宁联合甲氨蝶呤治疗类风湿关节炎临床疗效研究[D]. 湖北中医药大学, 2012.
[38] 陈蕊, 刘昌华. 正清风痛宁联合缬沙坦治疗糖尿病肾病38例临床观察[J]. 中医药导报, 2012, 18(11):56-57.
[39] 徐豫湘. 正清风痛宁缓释片治疗膝关节骨性关节炎的临床观察[D]. 湖南中医药大学, 2013.
[40] 刘天阳, 苏建明, 周学平. 正清风痛宁缓释片治疗回纹型风湿症疗效观察[J]. 辽宁中医药大学学报, 2013, 15(12):148-150.
[41] 李兆福, 刘维超, 彭江云,等. 蠲痹颗粒联合甲氨蝶呤片治疗活动性类风湿关节炎140例临床观察[J]. 中医杂志, 2014,55(18):1566-1570.
[42] 李强, 朱艳. 正清风痛宁联合西药治疗类风湿性关节炎随机平行对照研究[J]. 实用中医内科杂志, 2014, 28(7):86-88.
[43] 李兆福, 彭江云, 杨会军,等. 蠲痹颗粒治疗寒湿痹阻型类风湿关节炎60例临床观察[J]. 中国中医药科技, 2014, 21(3):291-292.
[44] 王文丽. 正清风痛宁治疗过敏性紫癜性肾炎临床观察[J]. 湖北中医杂志, 2014, 36(3):13-14.
[45] 廖勇, 游艳, 李璐. 正清风痛宁缓释片治疗老年回纹型风湿症的临床研究[J]. 中药药理与临床, 2015, 36(3):179-180.
[46] 吴媚荫. 正清风痛宁缓释片辨治回纹型风湿症的临床研究[J].新中医, 2015, 47(1):198-199.
[47] 许路军, 兰义成, 连晓江,等. 正清风痛宁缓释片联合厄贝沙坦治疗慢性肾炎蛋白尿30例临床观察[J]. 国医论坛, 2015,30(4):43-44.